1 rich Libsyn https://www.libsyn.com 90 600 It has become a problematic standard practice in the psychedelic therapy industry to increase drug dosages after patients display red flag symptoms. Psymposia discusses a recent Wall Street Journal article about these practices as they manifest in the ketamine industry; the psychedelic industry’s historic normalization of these practices; and recent attempts to convince lawmakers to protect psychedelic providers from liability for standard forms of medical malpractice. Together, these developments highlight why allowing a therapy cult to influence the norms of psychedelic medicine puts the public at risk. Footnotes: She Hoped Ketamine Would Rewire Her Brain. She Didn’t Live to See It Work. (WSJ): Live link: https://www.wsj.com/health/wellness/ketamine-telehealth-dangers-4a7bc8da Archive link: https://archive.is/qLxwO The Psychedelic Syndicate (Psymposia): https://www.psymposia.com/psychedelic-syndicate-executive-summary-silicon-valley-maps-lykos-mdma-fda-billionaires/ Hamilton’s Pharma Cope Series (Psymposia): https://www.psymposia.com/hamiltons-pharma-cope/ Colorado has a chance to get ibogaine policy right (Colorado Newsline): https://coloradonewsline.com/2026/02/17/colorado-get-ibogaine-policy-right/ &amp;nbsp; The Psymposia Podcast http://plusthree.libsyn.com <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/40819315/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/ed3037/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/200672430